Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Francis S. Willard(Eli Lilly (United States)), Kyle W. Sloop(Eli Lilly (United States))
JCI Insight
July 30, 2020
Cited by 468


Related Papers